Identificación y caracterización de eventos adversos asociados a la utilización de Cannabis: Revisión estructurada
DOI:
https://doi.org/10.30827/ars.v66i2.31894Palabras clave:
Cannabis, cannabis medicinal, cannabinoides, Revisión sistemática, cannabis recreacional, eventos adversos, revisión estructuradaResumen
Introducción: La disponibilidad de información estructurada de eventos adversos asociados al cannabis puede contribuir a la utilización adecuada del cannabis medicinal.
Objetivo: Sintetizar y caracterizar los eventos adversos asociados a la utilización de cannabis.
Método: Revisión estructurada de eventos adversos asociados a la utilización del cannabis en PubMed, utilizando términos Mesh (“Cannabis” And (“Drug-Related Side Effects or Adverse Reactions”), en humanos, publicados en inglés o español y acceso a texto completo, hasta noviembre 1 de 2024. Dos investigadores revisaron los artículos identificados y definieron su inclusión. Adicionalmente, se incluyeron referencias de artículos consideradas de interés.
Resultados: Se identificaron 47 eventos adversos asociados al uso de cannabis, afectando principalmente el sistema nervioso central y cardiovascular, en especial desórdenes mentales, somnolencia y afecciones gastrointestinales. No se identificaron eventos adversos mortales relacionados al uso de cannabis.
Conclusiones: La utilización de cannabis se asocia con la presentación de eventos adversos, en especial en los sistemas nervioso central y cardiovascular. Es necesario más estudios orientados a identificar y caracterizar eventos adversos asociados al cannabis.
Descargas
Citas
Skypala IJ, Jeimy S, Brucker H, et al. Cannabis-related allergies: An international overview and consensus recommendations. Allergy 2022; 77: 2038–2052. DOI: 10.1111/all.15237
Arnold JC, McCartney D, Suraev A, et al. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clin Transl Sci 2023; 16: 10–30. DOI: 10.1111/cts.13425
Marques Azzini GO, Marques Azzini VO, Santos GS, et al. Cannabidiol for musculoskeletal regenerative medicine. Exp Biol Med (Maywood) 2023; 248: 445–455. DOI: 10.1177/15353702231162086
Gottschling S, Ayonrinde O, Bhaskar A, et al. Safety Considerations in Cannabinoid-Based Medicine. Int J Gen Med 2020; 13: 1317–1333. DOI: 10.2147/IJGM.S275049
Choi NG, DiNitto DM, Marti CN, et al. Sex differences in cannabis forms and exposure reasons in cannabis-related poison control center cases aged 50. Clin Toxicol (Phila) 2021; 59: 822–831. DOI: 10.1080/15563650.2020.1869756
Subramaniam VN, Menezes AR, DeSchutter A, et al. The Cardiovascular Effects of Marijuana: Are the Potential Adverse Effects Worth the High? Mo Med 2019; 116: 146–153.
Arnold JC. A primer on medicinal cannabis safety and potential adverse effects. Aust J Gen Pract 2021; 50: 345–350. DOI: 10.31128/AJGP-02-21-5845
Lombardi E, Gunter J, Tanner E. Ohio physician attitudes toward medical Cannabis and Ohio’s medical marijuana program. J Cannabis Res 2020;2(1):16. DOI: 10.1186/s42238-020-00025-1.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;n71.
Bar-Sela G, Zalman D, Semenysty V, et al. The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. Integr Cancer Ther 2019; 18: 1534735419881498. DOI: 10.1177/1534735419881498
Crescioli G, Lombardi N, Bettiol A, et al. Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database. Br J Clin Pharmacol 2020; 86: 106–120. DOI: 10.1111/bcp.14140
Raghunathan NJ, Brens J, Vemuri S, et al. In the weeds: a retrospective study of patient interest in and experience with cannabis at a cancer center. Support Care Cancer 2022; 30: 7491–7497. DOI: 10.1007/s00520-022-07170-8
Richards JR. Mechanisms for the Risk of Acute Coronary Syndrome and Arrhythmia Associated With Phytogenic and Synthetic Cannabinoid Use. J Cardiovasc Pharmacol Ther 2020; 25: 508–522. DOI: 10.1177/1074248420935743
Rickner SS, Cao D, Kleinschmidt K, et al. A little ‘dab’ will do ya’ in: a case report of neuro-and cardiotoxicity following use of cannabis concentrates. Clin Toxicol (Phila) 2017; 55: 1011–1013. DOI: 10.1080/15563650.2017.1334914
Boukerche F, Khalil MZ, Shirk DV, et al. Serotonin Syndrome Misdiagnosed in a Patient Who Used a Cannabis Dab Pen. Prim Care Companion CNS Disord 2022; 24: 21cr03008. https://doi.org/10.4088/PCC.21cr03008
Mangot AG. Bad trip due to anticholinergic effect of cannabis. Gen Hosp Psychiatry 2013; 35: 682.e5–6. DOI: 10.1016/j.genhosppsych.2013.06.010
Bao C, Bao S. Neonate Death Due to Marijuana Toxicity to the Liver and Adrenals. Am J Case Rep 2019; 20: 1874–1878. DOI: 10.12659/AJCR.919545
Liskow B, Liss JL, Parker CW. Allergy to marihuana. Ann Intern Med 1971; 75: 571–573. DOI: 10.7326/0003-4819-75-4-571
Corso B, Bacle A, Demay E, et al. Place of therapeutic cannabis in France and safety data: A literature review. Ann Pharm Fr 2023; 81: 583–595. DOI: 10.1016/j.pharma.2023.02.002
Beck PJ, Reddy A. Cannabis Pen-Induced Psychosisin a First-Time Adolescent User. Psychopharmacol Bull 2023;53(3):61-5.
Nadeem Z, Wu C, Burke S, Parker S. Serotonin syndrome and cannabis: A case report. Australas Psychiatry 2024;32(1):100-1. DOI: 10.1177/10398562231219858
Krebs M-O, Kebir O, Jay TM. Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. Eur J Pain 2019; 23: 1225–1233. DOI: 10.1002/ejp.1377
Andréasson S, Allebeck P, Engström A, et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483–1486. DOI: 10.1016/s0140-6736(87)92620-1
Arendt M, Rosenberg R, Foldager L, et al. Cannabis-induced psychosis, and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005; 187: 510–515. DOI: 10.1192/bjp.187.6.510
Z Goldberger C, Dervaux A, Gourion D, et al. Variable individual sensitivity to cannabis in patients with schizophrenia. Int J Neuropsychopharmacol 2010; 13: 1145–1154. DOI: 10.1017/S1461145710000647
Sultan SR, Millar SA, O’Sullivan SE, et al. A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ8-Tetrahydrocannabinol. Pharmaceuticals (Basel) 2018; 11: 13. DOI: 10.3390/ph11010013
Beaumont H, Jensen J, Carlsson A, et al. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 2009; 156: 153–162. DOI: 10.1111/j.1476-5381.2008.00010.x
Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018; 391: 1085–1096. DOI: 10.1016/S0140-6736(18)30136-3
Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639–645. DOI: 10.1177/1352458505070618
Lorenzetti V, Solowij N, Yücel M. The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. Biol Psychiatry 2016; 79: e17-31. DOI: 10.1016/j.biopsych.2015.11.013
Gruber SA, Sagar KA. Marijuana on the Mind? The Impact of Marijuana on Cognition, Brain Structure, and Brain Function, and Related Public Policy Implications. Policy Insights Behav. Brain Sci 2017; 4: 104–111. DOI: 10.1177/2372732216684851
Karniol IG, Carlini EA. Comparative studies in man and in laboratory animals on 8 - and 9 -trans-tetrahydrocannabinol. Pharmacology 1973; 9: 115–126. DOI: 10.1159/000136375
Karniol IG, Shirakawa I, Takahashi RN, et al. Effects of delta9-tetrahydrocannabinol and cannabinol in man. Pharmacology 1975; 13: 502–512. DOI: 10.1159/000136944
Zimmer BD, Bickel P, Dittrich A. Changes of simple somatic parameters by delta-9-trans-tetrahydrocannabinol (delta-9-THC) in a double-blind-study. Short communication. Arzneimittelforschung 1976; 26: 1614–1616.
Haney M. Opioid Antagonism of Cannabinoid Effects: Differences between Marijuana Smokers and Nonmarijuana Smokers. Neuropsychopharmacol 2007; 32: 1391–1403. DOI: 10.1038/sj.npp.1301243
Klooker TK, Leliefeld KEM, Van Den Wijngaard RM, et al. The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol Motil 2011; 23: 30–35, e2. DOI: 10.1111/j.1365-2982.2010.01587.x
Gracie K, Hancox RJ. Cannabis use disorder and the lungs. Addiction 2021; 116: 182–190. DOI: 10.1111/add.15075
Lorenz DR, Uno H, Wolinsky SM, et al. Effect of marijuana smoking on pulmonary disease in HIV-infected and uninfected men: a longitudinal cohort study. EClinical Medicine 2019; 7: 55–64. DOI: 10.1016/j.eclinm.2019.01.003
Owen KP, Sutter ME, Albertson TE. Marijuana: respiratory tract effects. Clin Rev Allergy Immunol 2014; 46: 65–81. DOI: 10.1007/s12016-013-8374-y
Aviram J, Samuelly-Leichtag G. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Physician 2017; 20: E755–E796.
Monte AA, Shelton SK, Mills E, et al. Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Ann Intern Med 2019; 170: 531–537. DOI: 10.7326/M18-2809
WHO. The importance of pharmacovigilance. World Health Organization & WHO Collaborating Centre for International Drug Monitoring. Geneve: 2002.
Lopera V, Rodríguez A, Amariles P. Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review. J Clin Med 2022; 11: 1154. DOI: 10.3390/jcm11051154
Singh C, Rao K, Yadav N, et al. Current Cannabidiol Safety: A Review. Curr Drug Saf 2023;18(4):465-473. DOI: 10.2174/1574886317666220902100511
World Population Prospects - Population Division - United Nations. [Internet]. Population.un.org. Recuperado el 3 de noviembre de 2024, de https://population.un.org/wpp2019/
Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol 2021;18(11):785-802. DOI: 10.1038/s41569-021-00559-8
Solmi M, Toffol MD, Kim JY, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ 2023; 382: e072348. DOI: 10.1136/bmj-2022-072348
Sheikh NK, Dua A. Cannabinoids. 2023 Feb 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Langnas E, Maze M. Clinical Use of Adrenergic Receptor Ligands in Acute Care Settings. Handb Exp Pharmacol. 2024;285:617-637. DOI: 10.1007/164_2023_705
Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci 2020; 411: 116717. DOI: 10.1016/j.jns.2020.116717
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 Valeria Silva-Rivera, Valentina Lopera, Pedro Amariles
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Los artículos que se publican en esta revista están sujetos a los siguientes términos en relación a los derechos patrimoniales o de explotación:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, la cual se distribuirá con una licencia Creative Commons BY-NC-SA 4.0 que permite a terceros reutilizar la obra siempre que se indique su autor, se cite la fuente original y no se haga un uso comercial de la misma.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la fuente original de su publicación.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en repositorios institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
